BPC 157 peptide,
explained in depth.
A complete research library on BPC-157 — the synthetic pentadecapeptide derived from Body Protection Compound that has become the most-discussed healing peptide of the 2020s. Real mechanism of action, published dosing protocols, side effect data, and the regulatory history behind the most-researched fragment in the peptide world.
What is BPC 157 peptide?
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice called Body Protection Compound. It was first isolated and characterized at the University of Zagreb, Croatia, by Professor Predrag Sikirić's research group beginning in the 1990s. The peptide sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Preclinical research has examined its role in angiogenesis, tissue repair, gut healing, and neuroprotection. Despite thousands of citations in animal studies, BPC-157 remains unapproved for human use by any regulatory agency worldwide.
Every major BPC 157 topic, covered in depth.
Dosing protocols, mechanism of action, side effect data, and the full regulatory picture — built from the published clinical and preclinical literature, not from supplement-seller marketing copy.
BPC 157 dosage
Research protocols, vial reconstitution, subcutaneous injection math, half-life pharmacokinetics, and cycle length from published literature.
Read page → 02 / 10BPC 157 benefits
Mechanism of action, Sikirić's Croatia research program, and the molecular pathways behind BPC-157's tissue-repair effects.
Read page → 03 / 10BPC 157 side effects
Published safety data, WADA/FDA regulatory status, cancer and angiogenesis concerns, and the long-term risk questions that remain unanswered.
Read page → 04 / 10Wolverine peptide
The nickname origin, the podcast moment that mainstreamed it, and the relationship between "Wolverine peptide" and BPC-157.
Read page → 05 / 10BPC 157 and TB-500
The BPC-157 and TB-500 combination, the Wolverine Blend, complementary mechanisms, dosing, and research.
Read page → 06 / 10BPC 157 healing
Tendon, muscle, ligament, and bone repair research, realistic recovery timelines, and the preclinical mechanism behind tissue healing.
Read page → 07 / 10BPC 157 for gut health
Gut health research across IBS, IBD, leaky gut, and ulcer models — the strongest preclinical case in the BPC 157 literature.
Read page → 08 / 10Oral BPC 157 and administration routes
Capsules, sublingual troches, nasal spray, arginate salt, alkaline formulations, and injection routes — bioavailability and dosing by route.
Read page → 09 / 10BPC 157 peptide therapy
What supervised BPC 157 peptide therapy actually involves, the regulatory landscape, clinic red flags, and the potential HHS reclassification story.
Read page → 10 / 10BPC 157 cost and availability
Pricing across compounding pharmacies, research chemical markets, and clinical programs — plus where to buy and how to vet a vendor.
Read page →BPC 157 in five facts
| Fact | Detail |
|---|---|
| Origin | A synthetic 15-amino-acid (pentadecapeptide) fragment of Body Protection Compound, a protein isolated from human gastric juice. Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular formula C62H98N16O22, molecular weight 1419.55 g/mol. |
| Researcher of record | Characterized and advanced by Predrag Sikirić's group at the University of Zagreb, Croatia, beginning in the 1990s. The overwhelming majority of published BPC-157 research originates from this lab. |
| Mechanism | Promotes angiogenesis and tissue repair through activation of the VEGFR2, nitric oxide, FAK-paxillin, JAK-2, Egr-1, and ERK1/2 signaling pathways. Also modulates dopamine, serotonin, and prostaglandin systems in rodent models. |
| Clinical status | Thousands of preclinical studies, almost entirely in rats and mice. One Phase I human trial (42 volunteers) was completed in 2015 but results were never published. Small pilot studies in humans for interstitial cystitis (2024) and IV infusion safety (2025) have since appeared but remain uncontrolled. |
| Regulatory status | Not FDA-approved for any indication. Placed on the FDA's Category 2 list of bulk drug substances that may present significant safety risks in compounding. Classified S0 (Non-Approved Substances) on the WADA Prohibited List since 2022. Listed on the U.S. Department of Defense Prohibited Dietary Supplement Ingredients List. |
Spelling and naming FAQ
Is it spelled BPC-157 or BP-157?
The correct name is BPC-157, short for Body Protection Compound 157. Many people drop the "C" and write BP-157, or omit the hyphen and write BPC157 or BP157. All of these refer to the same synthetic 15-amino-acid peptide. See the common misspellings guide for the full list of variants.
What's the difference between BPC 157 and pentadecapeptide BPC 157?
There is no difference — "pentadecapeptide" simply specifies that the compound is a 15-amino-acid peptide, which BPC-157 is. The longer form appears in peer-reviewed literature to distinguish it from other Body Protection Compound fragments.
Why are there so many ways to spell BPC-157?
BPC-157 entered mainstream awareness relatively recently, primarily through podcasts and online discussion rather than print media. The combination of a three-letter acronym, a hyphen, and a number produces inconsistent autocorrect behavior, and most people encounter the name by ear before seeing it written. See the misspellings guide for details on each variant.